⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20513035 | 1.00 | — | — | |
| SCHEMBL999400 | 0.95 | — | — | |
| SCHEMBL2780260 | 0.86 | MEN1 (0.32) | — | |
| SCHEMBL1397639 | 0.79 | — | — | |
| SCHEMBL9952284 | 0.79 | — | — | |
| SCHEMBL17460346 | 0.79 | — | — | |
| SCHEMBL3393452 | 0.77 | — | — | |
| SCHEMBL23765660 | 0.76 | MEN1 (0.38) | — | |
| SCHEMBL19107454 | 0.76 | MEN1 (0.38) | — | |
| SCHEMBL2639323 | 0.76 | MEN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190936-A1 | Incretin Analogs and Uses Thereof | ELI LILLY AND COMPANY | 2024-06-13 | — | — | US | claimed |
| EP-4199946-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | SANOFI SA (FR) | 2024-06-05 | — | — | EP | claimed |
| CN-118021978-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2024-05-14 | — | — | CN | claimed |
| WO-2024067662-A1 | GLP-1/GCG/GIP TRIPLE-RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业股份有限公司 | 2024-04-04 | — | — | WO | claimed |
| EP-4331674-A2 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2024-03-06 | — | — | EP | claimed |
| CN-117320740-A | GIP/GLP1 dual agonist treatment methods | 伊莱利利公司 | 2023-12-29 | — | — | CN | claimed |
| US-11851468-B2 | Treatment of neurological diseases | UNIVERSITY OF LANCASTER (GB) | 2023-12-26 | — | — | US | claimed |
| US-11834486-B2 | Incretin analogs and uses thereof | ELI LILLY AND COMPANY (US) | 2023-12-05 | — | — | US | claimed |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | claimed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-1853627-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| JP-2007525495-A | — | — | 2007-09-06 | — | — | JP | claimed |
| EP-1796709-A2 | ANALOGS OF SHK TOXIN AND THEIR USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2007022123-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | claimed |
| EP-1718665-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2006086769-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
| WO-2006042151-A2 | ANALOGS OF SHK TOXIN AND THEIR USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2005077072-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | claimed |